Research Study for Adults with Inoperable Liver Cancer


16105

A Phase III Clinical Trial of Intra-arterial TheraSphere in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC)

Radiology

Stone James, R

UVa Health System seeks adults with inoperable liver cancer called hepatocellular carcimoma or HCC for a research study. The purpose of the study is to determine if the investigational device, TheraSphere®, when given before the o standard of care chemotherapy called sorafenib extends survival time and is safe. TheraSphere® contains a radioactive material called yttrium-90 (Y-90). TheraSphere® is injected into the main blood vessel in the liver to deliver radiation therapy directly to the tumor. This allows for higher doses of radiation to get to the tumor and spares the healthy surrounding tissue. . Study participation involves being randomly assigned to receive standard treatment with sorafenib or standard treatment with sorafenib plus TheraSphere®. * Study device, TheraSphere®, and procedures performed for research purposes will be provided at no cost. * Participant’s insurance company will be billed for standard of care medication, tests and procedures. * No compensation is provided for this study. For more information please contact: • Brigitte Kelly • 434-297-7136 / bjk3c@virginia.edu • IRB-HSR # 16105 Principal Investigator: James R. Stone, MD, PhD



Liver Cancer

Cancer (Oncology)

Ill

No Compensation

Brigitte Kelly

bjk3c@virginia.edu

4342977136